moderate Severity

Biocide Allergy: The MI Epidemic, Its BIT Successor, and Formaldehyde Releasers

Biocide contact allergy โ€” particularly to methylisothiazolinone (MI) and its successor benzisothiazolinone (BIT) โ€” represents one of the most significant contact allergy epidemics of the 21st century. MI sensitization peaked at 15.0% in NACDG 2017-18 after consumer flight from parabens drove its widespread adoption. EU bans have reduced European rates; US rates remain high at 11.5%. BIT is emerging as the next epidemic at 10.4% (NACDG 2019-20). Formaldehyde releasers remain significant allergens.

moderatePeak: Year-roundUpdated April 10, 2026

Free ยท 5 min ยท Insurance accepted

Reviewed by Dr. Chet Tharpe, M.D.
As seen inUSA TODAYMen's HealthCBSForbes
The numbers
Headline stat
0%
MI PEAK RATE (NACDG)
US prevalence
0.0%
Peak season
Year-round
Symptoms tracked
0
Treatment paths
0
01Overview

What Are Biocides and Why Do They Cause Contact Allergy?

Biocides are chemicals that kill or suppress microorganisms โ€” bacteria, molds, and yeasts โ€” to preserve products from spoilage and contamination.

In cosmetics, personal care products, and household cleaning formulations, biocides function as preservatives, extending shelf life and preventing potentially dangerous microbial contamination in water-containing products. The need for preservation is genuine: water-based products without any preservatives can harbor bacteria and fungi that cause skin infections and product degradation.

The central challenge in cosmetic and industrial preservation is the 'preservative dilemma': the same chemical properties that make biocides effective antimicrobials โ€” reactivity with microbial proteins and cell membranes โ€” also create potential for skin protein reactivity and immune sensitization. The more potent the antimicrobial, the higher the sensitization risk.

This page covers the most clinically important biocide contact allergens: the isothiazolinones (methylisothiazolinone/MI, methylchloroisothiazolinone/MCI, and benzisothiazolinone/BIT) and the formaldehyde releasers (quaternium-15, DMDM hydantoin, imidazolidinyl urea, diazolidinyl urea, and bronopol). These are among the most prevalent contact allergens in current patch test practice โ€” not rare theoretical concerns but major drivers of population-level sensitization.

02Symptoms

Symptoms of MI, BIT, and Formaldehyde Releaser Contact Allergy

Recognizing symptoms early helps you get the right treatment faster.

Facial eczema (cosmetic exposure)

moderate

Pruritic erythema, scaling, and vesiculation on the face from MI in moisturizers, sunscreens, or facial cleaners โ€” often initially attributed to a new product.

Eyelid dermatitis

moderate

Thin eyelid skin is highly susceptible to MI and formaldehyde releaser contact allergy; presents as swollen, red, scaly, intensely itchy eyelids.

Scalp and hairline dermatitis

moderate

Eczematous reaction at the hairline, behind the ears, and on the neck from MI-preserved shampoos and conditioners.

Hand and occupational dermatitis

moderate

Painters and wet workers develop hand and forearm eczema from repeated MI exposure in water-based paints and industrial cleaners.

Fabric contact pattern eczema

moderate

MI residue in laundered clothing causes eczema at fabric contact sites โ€” trunk, inner thighs, axillae โ€” mimicking other conditions and typically delayed 24โ€“72 hours after wearing freshly laundered clothes.

Airborne contact dermatitis (painters)

moderate

Aerosolized MI from water-based paints deposits on facial and eyelid skin of painters, producing airborne contact dermatitis in areas not directly touching painted surfaces.

Widespread generalized dermatitis

severe

Severely sensitized individuals using multiple MI-containing products daily may develop widespread eczema across the body, which can be debilitating and difficult to connect to a single cause without patch testing.

When to see a doctor

Contact allergy to biocide preservatives presents as allergic contact dermatitis โ€” a pruritic, eczematous reaction at sites of allergen contact. The distribution reflects exposure patterns: cosmetic MI allergy typically affects the face (from moisturizers), scalp and hairline (from shampoos), or body (from body lotions). Industrial MI exposure from paints causes hand and forearm eczema in painters. Formaldehyde releaser allergy follows product use patterns โ€” face, neck, hands, or clothing contact sites. A critical diagnostic challenge is the 'fabric contact pattern': when MI-preserved laundry products leave residues in clothing, eczema may appear at truncal clothing contact sites โ€” a pattern easily misattributed to food allergy, internal disease, or other causes. Recognizing the fabric contact distribution and testing the laundry product hypothesis is essential. Airborne MI exposure in painting environments can produce facial and eyelid eczema from aerosol deposition โ€” a pattern resembling photodermatitis or inhalant allergy. Seek medical attention for any widespread or rapidly spreading eczematous reaction, or if facial swelling accompanies skin symptoms.

Biocides and Respiratory Effects

Isothiazolinone biocides (MI, BIT) are not established causes of IgE-mediated allergic asthma. Their primary health impact is through cutaneous sensitization and contact dermatitis. However, occupational inhalation of MI-containing paints, coatings, or cleaning products at high concentrations has been associated with respiratory irritation and โ€” in a small number of reported cases โ€” occupational asthma through a non-classical mechanism. This is distinct from the well-characterized skin sensitization pathway. Formaldehyde, released by formaldehyde-releasers, is both a contact allergen and a respiratory irritant. Formaldehyde inhalation at occupational concentrations causes nasal and bronchial irritation and has been associated with occupational rhinitis in pathology and anatomy laboratory workers, funeral home staff, and those working in formaldehyde-rich manufacturing environments. Individuals with pre-existing asthma should minimize occupational formaldehyde exposure.

If left untreated

Complications of Biocide Contact Allergy

MI and formaldehyde releaser contact allergy has significant lifestyle impacts because these preservatives appear in so many product categories. A patient sensitized to MI must potentially replace their moisturizer, sunscreen, shampoo, body wash, household cleaners, laundry detergent, wipes, and workplace products simultaneously. The burden of vigilant label reading and product replacement is substantial. The MCI/MI patch testing gap creates a diagnostic complication: standard patch testing with MCI/MI (Kathon CG) at 100 ppm aqueous misses approximately 40% of MI-only allergies. Patients tested only with MCI/MI who are negative may still be MI-sensitized โ€” separate MI testing at 0.2% aqueous is essential for complete evaluation. Many patients are inadequately diagnosed due to this testing limitation. BIT sensitization expanding to 10.4% in NACDG 2019-20 parallels early MI trajectory, suggesting we may be in the early stages of a new epidemic โ€” particularly concerning given that BIT is replacing MI in many industrial and household products following EU restrictions.

Broad product cross-reactivity and lifestyle burden

MI sensitization requires vigilant avoidance across dozens of product categories; the cumulative burden of label-reading and product replacement significantly affects quality of life.

Missed diagnosis from inadequate patch testing

MCI/MI testing at standard concentrations misses ~40% of MI-only allergies; patients may remain undiagnosed and continue using MI-containing products without understanding the cause of their dermatitis.

Formaldehyde releaser cross-reactivity

Patients sensitized to formaldehyde must also avoid all formaldehyde releasers (quaternium-15, DMDM hydantoin, etc.), which are present in many different product categories โ€” expanding avoidance requirements substantially.

Occupational implications for painters and cleaners

Professional painters sensitized to MI in water-based paints face occupational accommodation challenges; switching to solvent-based or MI-free water-based paints may be required.

03Why it happens

The MI Epidemic: How Consumer Behavior Created a Public Health Crisis

The methylisothiazolinone (MI) epidemic is a case study in how well-intentioned consumer behavior and incomplete safety data can collide to create widespread harm. In the early 2000s, consumer advocacy groups raised concerns about parabens in cosmetics โ€” concerns largely based on misinterpreted science about estrogenic activity. Consumer demand for 'paraben-free' products surged, and cosmetic manufacturers sought replacement preservatives. MI was approved for use alone in leave-on cosmetics at 100 parts per million (ppm) around 2005, based on LLNA (Local Lymph Node Assay) data that significantly underestimated its sensitization potential in humans.

MI and MCI/BIT are electrophilic thiol-reactive chemicals that bind covalently with cysteine residues in skin proteins, forming hapten-protein conjugates. These conjugates are processed by Langerhans cells and dendritic cells in the epidermis, which migrate to regional lymph nodes and activate allergen-specific T lymphocytes โ€” the sensitization phase of Type IV delayed hypersensitivity. On re-exposure, sensitized T cells recognize MI-protein conjugates and mount an inflammatory cascade producing eczematous dermatitis 24โ€“72 hours after contact. Formaldehyde releasers sensitize through the same mechanism as formaldehyde itself โ€” formaldehyde is released into the product matrix where it reacts with skin proteins to form immunogenic Schiff base adducts.

MI use surged in cosmetics, personal care products, and household cleaners throughout the late 2000s and early 2010s. The result was catastrophic from a sensitization standpoint: MI rates in patch test populations rose from negligible to a peak of 15.0% in NACDG 2017-18 and 9.39% in UK data by 2013. Critically, this occurred not because people are unusually reactive, but because MI is a genuinely potent sensitizer that was deployed at concentrations generating population-level sensitization.

BIT (benzisothiazolinone) is now following an eerily similar trajectory as a 'safer' replacement for MI in household and industrial products: โ‰ค0.3% sensitization in 2014, rising to 5.0% in Danish data and 10.4% in NACDG 2019-20. The parallel with early MI is troubling.

Formaldehyde releasers โ€” quaternium-15, DMDM hydantoin, imidazolidinyl urea, diazolidinyl urea, and bronopol โ€” work by slowly releasing low levels of formaldehyde into products. Formaldehyde is itself an IARC Group 1 carcinogen and a significant contact allergen (NACDG ~7.8% at 2% aqueous). Formaldehyde releasers carry their own sensitization rates: quaternium-15 is the most potent (7.7% NACDG; now banned in EU cosmetics), DMDM hydantoin ~2.8%, imidazolidinyl urea ~3%, diazolidinyl urea 2โ€“4%, and bronopol ~3.3%.

Who's most affected

Risk factors to watch for

01

Regular use of MI-containing cosmetics or personal care products

Daily application of leave-on products (moisturizers, sunscreens, body lotions) containing MI at concentrations up to 100 ppm generates sustained skin protein reactivity and progressive sensitization risk.

02

Wet work occupations

Healthcare workers, cleaners, caterers, and hairdressers who perform wet work have higher skin exposure to industrial preservatives including MI, BIT, and formaldehyde releasers.

03

Use of MI-preserved paints and building materials

Water-based paints, adhesives, and building products frequently contain high concentrations of MI as an in-can preservative โ€” exposure during DIY painting and renovation is a significant non-cosmetic source.

04

Atopic skin barrier impairment

Compromised skin barrier allows greater penetration of MI and related biocides into the skin, increasing the concentration available for hapten-protein conjugation and sensitization.

05

Pre-existing formaldehyde sensitivity

Patients sensitized to formaldehyde are at risk of reactions from any formaldehyde-releasing preservative across all product categories โ€” a single sensitization creates broad cross-reactivity.

The Allergy Cascade

1.Exposure

Allergen contact

2.Detection

Immune recognition

3.IgE Response

Antibody production

4.Mast Cells

Histamine release

5.Symptoms

Allergic reaction

05Diagnosis

Diagnosing Biocide Contact Allergy: The Testing Gaps Matter

Patch testing is the gold standard for diagnosing biocide contact allergy. For the isothiazolinones, the testing protocol requires attention to which agents are included: MCI/MI (Kathon CG, 3:1 ratio) is tested at 100 ppm aqueous in the standard NACDG and European Baseline Series โ€” but this combination misses approximately 40% of MI-only allergies. Separate MI testing at 0.2% aqueous is essential and should be performed alongside MCI/MI to avoid false negatives. BIT is now being added to extended series in many centers given its rising prevalence. Formaldehyde is tested at 2% aqueous (NACDG rate ~7.8%); formaldehyde releasers (quaternium-15, DMDM hydantoin, imidazolidinyl urea, diazolidinyl urea, bronopol) should also be tested individually. Patch testing typically takes 4โ€“7 days: allergens applied on Day 0, removed at 48 hours, first reading at 48โ€“72 hours, second reading at 96 hours. Late readings at Day 7 may be needed for metals but are generally not required for isothiazolinones. Product testing can supplement standard series: patients bring their suspect cosmetics and cleaners for ROAT (repeated open application test) or diluted patch testing when standard series do not capture the specific product preservative. At-home allergy testing services such as Curex offer comprehensive panels covering 40+ IgE-mediated allergens including environmental allergens, pet dander, and food allergens โ€” useful for evaluating co-existing IgE-mediated conditions. However, biocide contact allergy is Type IV (not IgE-mediated) and requires patch testing by a dermatologist. The two testing modalities evaluate fundamentally different immune mechanisms.

MCI/MI patch testing (100 ppm aqueous)

Standard baseline series allergen for combined methylchloroisothiazolinone and methylisothiazolinone sensitization. Included in NACDG and European Baseline Series. Critical limitation: misses ~40% of MI-only allergies.

MI alone (0.2% aqueous)

Separate methylisothiazolinone testing essential for identifying MI-only sensitized patients who test negative on MCI/MI. Required for complete evaluation in suspected MI allergy.

Formaldehyde (2% aqueous) and formaldehyde releasers

Formaldehyde plus individual releasers (quaternium-15, DMDM hydantoin, imidazolidinyl urea, diazolidinyl urea, bronopol) should be tested together. Positive formaldehyde result indicates avoidance of all releasers.

BIT (benzisothiazolinone)

Emerging allergen with 10.4% positivity (NACDG 2019-20); now being added to extended panels in many centers. Important for evaluation when standard MI testing is negative but household/industrial product exposure is suspected.

At-home testing

Test from home with Curex

Skip the clinic visit. Curex sends an at-home allergy test kit to your door, and a board-certified allergist reviews your results to build a personalized treatment plan.

Take the allergy quiz
Insurance acceptedBoard-certified allergists
06Treatment

Managing Biocide Contact Allergy: Avoidance, Barrier Care, and Label Reading

See how different approaches stack up for managing your allergy symptoms long-term.

There is no cure for biocide contact allergy โ€” the immune sensitization persists indefinitely once established. Management is entirely avoidance-based: identifying and eliminating MI, BIT, and formaldehyde releaser exposures across all product categories. The remarkable complexity is that these preservatives appear in dozens of product types โ€” cosmetics, cleaning products, baby wipes, paper products, paints, and even some medications.

Acute allergic contact dermatitis is treated with topical corticosteroids and emollients. Severe widespread dermatitis may require a short course of systemic corticosteroids under physician supervision. Chronic hand dermatitis is managed with moisturizers, barrier protection, and periodic topical anti-inflammatory therapy.

The EU has taken regulatory action: MI banned from leave-on cosmetics in 2017, restricted in rinse-off products to 15 ppm in 2018. Quaternium-15 is banned in EU cosmetics. These regulatory interventions are associated with declining EU MI rates โ€” a regulatory success story. In the US, there are no equivalent federal restrictions, and MI remains common in consumer products.

Complete MI and formaldehyde releaser avoidance

Once sensitized, avoiding all products containing MI, MCI, BIT, and formaldehyde releasers across cosmetics, cleaning products, and household items. Label reading is essential โ€” these ingredients may appear under multiple names.

N/A โ€” allergen avoidance strategy

Highly effective โ€” dermatitis resolves within weeks of comprehensive allergen elimination

Ingredient name education

Patients must recognize multiple names: MI appears as 'methylisothiazolinone,' 'MIT,' 'neolone 950'; MCI as 'methylchloroisothiazolinone,' 'Kathon CG'; BIT as 'benzisothiazolinone'; quaternium-15 as 'Dowicil 200.' Many resources (ACDS Contact Allergy Resource Center) provide complete lists.

N/A

Essential for successful avoidance; patients who learn to read labels experience significantly fewer re-exposure reactions

Topical corticosteroids

Mid-to-high potency topical corticosteroids applied twice daily to active eczema reduce inflammation during flares. Selection of strength based on body site and dermatitis severity under dermatologist guidance.

Hydrocortisone 1-2.5% (mild areas), triamcinolone 0.1%, mometasone furoate, clobetasol 0.05% (hands, scalp)

Effective for acute flare control; do not prevent re-exposure reactions

Calcineurin inhibitors

Tacrolimus (Protopic) and pimecrolimus (Elidel) are non-steroidal topical immunosuppressants useful for eyelid and facial eczema where steroid risks are highest.

Tacrolimus 0.03โ€“0.1% (Protopic), pimecrolimus 1% (Elidel)

Comparable to moderate-strength topical steroids for face and eyelids without steroid side effects

Fragrance-free, MI-free emollients

Daily moisturizer use with products confirmed free of MI, fragrances, and formaldehyde releasers maintains skin barrier between exposures and reduces severity of any breakthrough reactions.

Vanicream, CeraVe (check specific formulation), Cetaphil Restoraderm (confirm MI-free)

Consistent moisturizer use significantly reduces overall eczema severity and frequency

Traditional

  • NoTreats root cause
  • NoLong-lasting relief
  • YesAt-home treatment
  • YesNo office visits
  • PartialLow side effects
  • PartialEstimated cost

Allergy Shots (SCIT)

  • YesTreats root cause
  • YesLong-lasting relief
  • NoAt-home treatment
  • NoNo office visits
  • PartialLow side effects
  • PartialEstimated cost

Immunotherapy (SLIT)

Recommended
  • YesTreats root cause
  • YesLong-lasting relief
  • YesAt-home treatment
  • YesNo office visits
  • YesLow side effects
  • YesEstimated cost
Immunotherapy

Immunotherapy for Biocide Contact Allergy

Instead of masking symptoms, immunotherapy retrains your immune system.

Standard allergen immunotherapy (SLIT or SCIT) is not an established treatment for biocide contact allergy. Isothiazolinones and formaldehyde releasers are small reactive chemical haptens rather than complete protein allergens; there are no standardized immunotherapy formulations for these chemicals, and no published clinical trials of desensitization for MI or formaldehyde releaser contact allergy. The treatment model remains avoidance-based. However, for patients who have co-existing IgE-mediated allergic conditions โ€” such as atopic dermatitis driven by dust mite or environmental IgE sensitization โ€” sublingual immunotherapy targeting those underlying conditions may improve overall skin health and barrier integrity, reducing the threshold at which biocide exposures cause clinically significant reactions. Sublingual immunotherapy, offered by providers like Curex, delivers custom-formulated allergen drops under the tongue and can be taken at home โ€” eliminating weekly clinic visits required for allergy shots. Plans have program-specific pricing (https://getcurex.com/learn/curex-pricing); insurance billing for testing and consultations depends on your plan. In a real-world Curex study of 2,897 patients on at-home sublingual immunotherapy (Tharpe et al., Frontiers in Allergy, 2026), clinically meaningful symptom improvement rose to 45% of patients by two years, with quality-of-life improvement reaching 90.7% and adherence over 90%. For patients with both biocide contact allergy and underlying atopic IgE-mediated disease, treating the IgE component with SLIT can be a meaningful part of comprehensive allergy management โ€” even though SLIT does not address the contact sensitization itself.

1Step 1

Identify all biocide allergens with patch testing

Complete patch testing including MI alone, MCI/MI combined, BIT, and formaldehyde/releasers establishes the full sensitization profile.

2Step 2

Systematically replace all allergen-containing products

Working through cosmetics, cleaning products, and household items to identify and replace MI/BIT/formaldehyde releaser-containing products.

3Step 3

Evaluate for underlying IgE-mediated conditions

If atopic dermatitis or IgE-mediated allergies co-exist, consider SLIT to reduce the atopic background that amplifies contact allergy severity.

4Step 4

Maintain barrier and monitor for new product exposures

Ongoing label reading, consistent emollient use, and awareness that product reformulations may reintroduce allergens over time.

โ€œContact allergy avoidance with verified allergen-free products resolves active eczema in the majority of cases within 4โ€“12 weeksโ€

Curex drops

Treat your Biocide allergy at the source

See if at-home sublingual allergy drops fit your allergies โ€” a 2-minute quiz, designed by board-certified allergists, with no needles and no clinic visits.

  • MD-led
    Board-certified allergists
  • Plan-specific
    Pricing ยท Confirm your quote
  • 50K+
    Patients treated
  • HSA/FSA
    Eligible
Living with it

Daily Life With MI and Formaldehyde Releaser Contact Allergy

Living with biocide contact allergy primarily means becoming a diligent ingredient label reader โ€” a habit that becomes second nature for most patients over time. The ACDS Contact Allergy Management Program (CAMP) database is an invaluable resource: after patch testing identifies specific allergens, CAMP can generate a customized list of allergen-free products across product categories, reducing the burden of individual label checking. Product reformulation is an ongoing challenge: manufacturers change formulations without notice, so a product that was safe at one time may later contain the allergen. Periodic re-checking of trusted products, especially when packaging changes, is worthwhile. For occupational MI exposure in painting, discussing MI-free paint specifications with employers or clients, or switching to low-MI/MI-free products when personal purchasing control is available, is the key workplace adaptation.

  • The CAMP database is your best resource

    After your dermatologist performs patch testing, the ACDS Contact Allergy Management Program (CAMP) generates a personalized list of products free of your confirmed allergens. This is significantly more efficient than checking individual product labels and is the standard of care recommendation after patch testing.

  • Know the EU regulatory context

    EU-formulated products (check packaging country of manufacture) are more likely to be MI-free for leave-on products because of the EU 2017 ban. US-formulated products may still contain MI at up to 100 ppm in leave-on products โ€” the regulatory environment matters for product safety.

  • Manage relationships with personal care services

    Informing hair salons, massage therapists, facial estheticians, and other personal care providers about your MI allergy before services allows them to check product labels in advance โ€” preventing exposure during services that use high-volume products not under your direct control.

Biocide Allergen Exposure: Year-Round With Summer Paint Peak

Biocide contact allergy from cosmetics and personal care products is entirely year-round, driven by daily product use patterns. Unlike seasonal allergens, MI and formaldehyde releaser exposure has no temporal pattern โ€” affected individuals use moisturizers, shampoos, and household cleaners throughout the year. One meaningful seasonal variation exists for paint and building material exposure: spring and summer are peak home renovation and painting seasons. Water-based paints containing MI as an in-can preservative are a major non-cosmetic source of MI exposure. Painters โ€” professional and DIY โ€” have disproportionately high rates of MI sensitization from in-can preservatives released when paint is mixed and applied, with aerosolized MI reaching airway and skin surfaces. This seasonal occupational exposure peak correlates with increased MI-related contact allergy presentations in dermatology clinics in late spring and summer.

Year-round

January - December

high intensity

Spring

March - May

high intensity

Summer

June - August

high intensity

Preventing Biocide Sensitization: Label Reading and Product Choice

While not all sensitization can be prevented โ€” particularly in occupational settings โ€” consumers can significantly reduce their risk by making informed product choices. Choosing MI-free, formaldehyde releaser-free products is the most actionable prevention strategy for anyone who has not yet sensitized, and the definitive management strategy for those who have. The 'paraben paradox' is an important preventive lesson: parabens, which have sensitization rates of ~1%, were largely replaced by MI, which peaks at 15%. Before switching products based on marketing claims ('paraben-free,' 'natural'), it is worth understanding what replaces the ingredient being avoided โ€” the replacement may be significantly more sensitizing.

Read ingredient labels for MI under all names

MI appears as 'methylisothiazolinone,' 'MIT,' and 'neolone 950.' MCI appears as 'methylchloroisothiazolinone.' BIT appears as 'benzisothiazolinone.' Know all synonyms.

Recognize formaldehyde releasers by name

Quaternium-15 ('Dowicil 200'), DMDM hydantoin, imidazolidinyl urea, diazolidinyl urea, and bronopol all release formaldehyde โ€” patients sensitized to any one should avoid all.

Do not assume 'natural' means allergen-free

Many 'natural' and 'organic' products contain MI or BIT as preservatives; the 'natural' label has no regulatory definition in the US and does not guarantee biocide-free formulation.

Be vigilant about water-based paints

DIY painters should be aware that water-based interior paints commonly contain MI at high concentrations. Ventilate painting areas well and wash skin after paint contact. Low-MI or MI-free paint formulations are available.

Use ACDS and CAMP resources

The American Contact Dermatitis Society (ACDS) Contact Allergy Management Program (CAMP) provides allergen-free product databases โ€” use these after patch testing to find safe product alternatives systematically.

Do not replace parabens with unproven alternatives

Parabens have a strong safety track record at ~1% sensitization. Replacing them based on marketing fears may expose you to worse alternatives โ€” consult the ACDS for evidence-based guidance.

Long-term outlook

Prognosis for Biocide Contact Allergy

The contact sensitization to MI and formaldehyde releasers is lifelong โ€” once sensitized, the immune memory persists. However, the prognosis for quality of life is good with comprehensive allergen avoidance. The vast majority of patients with diagnosed MI contact allergy experience complete resolution of active dermatitis within 4โ€“12 weeks of successfully eliminating all allergen-containing products. Maintaining remission requires permanent vigilance about product ingredients. Inadvertent re-exposures โ€” from a new product containing MI, a reformulated trusted product, or an occupation-related exposure โ€” produce flares that are managed the same way: stop exposure, treat the acute dermatitis, and resume avoidance. The broader epidemiological prognosis is concerning: BIT rates (10.4% NACDG 2019-20) are approaching early MI epidemic levels. Without proactive regulatory intervention similar to the EU's MI restrictions, a BIT epidemic similar to MI's appears likely in the US over the next decade.

What to expect

Key takeaways

01

MI sensitization peaked at 15.0% (NACDG 2017-18) โ€” driven by consumer 'paraben-free' demand replacing parabens with a far more potent sensitizer

02

BIT is emerging as a replacement for MI with sensitization rates of 10.4% (NACDG 2019-20) โ€” potentially the next epidemic allergen

03

MCI/MI patch testing misses ~40% of MI-only allergies โ€” separate MI testing at 0.2% aqueous is essential for complete diagnosis

04

Comprehensive allergen avoidance using the ACDS CAMP database resolves active dermatitis in the majority of cases within weeks

05

Parabens โ€” with ~1% sensitization โ€” have proven far safer than their replacements; the 'paraben panic' caused the MI epidemic

The methylisothiazolinone epidemic is the clearest example of how consumer marketing caused a public health crisis โ€” parabens were safe at 1 percent sensitization, but 'paraben-free' labeling drove a switch to MI, which peaked at 15 percent. I now test every eczema patient with separate MI at 0.2 percent, because standard MCI/MI misses 40 percent of MI-only cases.

Board-certified allergist (clinical reviewer for this article)
FAQ

Frequently Asked Questions

Methylisothiazolinone (MI) is a biocide preservative used in cosmetics, personal care products, household cleaners, and industrial products to prevent microbial contamination. It became a major problem when consumer demand for 'paraben-free' products drove its widespread adoption in the mid-2000s, based on incomplete safety data. MI proved to be a potent contact sensitizer: rates peaked at 15.0% in NACDG patch test populations by 2017-18 โ€” among the highest ever recorded for a common contact allergen. The EU banned MI from leave-on cosmetics in 2017; the US has no equivalent restrictions, and rates remain high.

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.

Get started today

Ready to treat your Biocide allergies for good?

Get a personalized treatment plan from board-certified allergists, delivered to your door.

Reviewed by board-certified allergists. Personalized treatment plans based on your at-home IgE test, not generic protocols.

Compare Curex plan pricing
3-minute quizBoard-certified allergistsProgram-specific pricing ยท Confirm your written quote

Questions about Curex itself?

Straight answers about the company, the evidence, what patients report, and what it costs โ€” including the parts that are not flattering.

Find out what you're actually allergic to โ€” and treat the cause

Take the free allergy quiz

Ready to treat your allergies at the source?

Take the free allergy quiz to find out if immunotherapy is right for you and get started with personalized treatment today.

Take Free Allergy Quiz